title: Does Pro(12)Ala Polymorphism Enhance the Physiological Role of PPARγ2?
abstract: Obesity and type 2 diabetes mellitus (T2D) are two major public health problems that have motivated the scientific community to investigate the high contribution of genetic factors to these disorders. The peroxisome proliferator activated by gamma 2 (PPARγ2) plays an important role in the lipid metabolism. Since PPARγ2 is expressed mainly in adipose tissue, a moderate reduction of its activity influences the sensitivity to insulin, diabetes, and other metabolic parameters. The present study aims to contribute to the elucidation of the impact of the Pro(12)Ala polymorphism associated with T2D and obesity through a meta-analysis study of the literature that included approximately 11500 individuals, from which 3870 were obese and 7625 were diabetic. Statistical evidence supports protective effect in T2D of polymorphism Pro(12)Ala of PPARγ2 (OR = 0.702 with 95% CI: 0.622; 0.791, P < 0.01). Conversely the same polymorphism Pro(12)Ala of PPARγ2 seems to favor obesity since 1.196 more chance than nonobese was found (OR = 1.196 with 95% CI: 1.009; 1.417, P < 0.004). Our results suggest that Pro(12)Ala polymorphism enhances both adipogenic and antidiabetogenic physiological role of PPARγ. Does Pro(12)Ala polymorphism represent an evolutionary step towards the stabilization of the molecular function of PPARγ transcription factor signaling pathway?
authors: Unit of Molecular Mechanisms of Disease (CISA) and Chemical and Biomolecular Sciences, School of Allied Health Sciences, Polytechnic Institute of Porto (ESTSP-IPP), Portugal ; Center of Pharmacology and Chemical Biopathology (U38-FCT), Medical Faculty, University of Porto, Portugal.
authors: A C
authors: AC
authors: Pereira
authors: R
authors: R
authors: Oliveira
authors: A C
authors: AC
authors: Castro
authors: R
authors: R
authors: Fernandes
references: Exp Gerontol. 2005 Jul;40(7):599-604
references: 16029943
references: Diabetologia. 2006 Jan;49(1):158-68
references: 16362285
references: Nature. 2001 Dec 13;414(6865):782-7
references: 11742409
references: Int J Obes Relat Metab Disord. 2000 Mar;24(3):391-3
references: 10757637
references: Best Pract Res Clin Gastroenterol. 2004 Dec;18(6):1125-46
references: 15561643
references: PPAR Res. 2009;2009:849538
references: 19390629
references: Folia Biol (Praha). 2004;50(5):153-6
references: 15581066
references: Diabetes Metab. 2005 Apr;31(2):119-23
references: 15959417
references: J Clin Endocrinol Metab. 2000 May;85(5):1801-4
references: 10843155
references: Clin Biochem. 2009 Nov;42(16-17):1642-7
references: 19733160
references: Biochim Biophys Acta. 2007 Aug;1771(8):1108-12
references: 17493868
references: J Biomed Biotechnol. 2009;2009:126917
references: 19125195
references: Cell. 1995 Dec 15;83(6):835-9
references: 8521507
references: Diab Vasc Dis Res. 2010 Jan;7(1):56-62
references: 20368233
references: Diabetes. 2001 Apr;50(4):891-4
references: 11289058
references: Diabetologia. 2002 Jan;45(1):152-3
references: 11845236
references: Diabetes Res Clin Pract. 2003 Nov;62(2):105-11
references: 14581147
references: PPAR Res. 2009;2009:874126
references: 19859551
references: Diabetes. 2002 Aug;51(8):2581-6
references: 12145174
references: Curr Opin Clin Nutr Metab Care. 2007 Mar;10(2):142-8
references: 17285001
references: Diabetes. 2002 Mar;51(3):867-70
references: 11872694
references: J Clin Endocrinol Metab. 1999 Oct;84(10):3708-12
references: 10523018
references: BMC Med Genet. 2005 Mar 22;6:11
references: 15784141
references: EXS. 2000;89:141-51
references: 10997287
references: Diabetes. 2001 Apr;50(4):876-81
references: 11289055
references: Eur J Endocrinol. 2002 Oct;147(4):495-501
references: 12370112